|
||
Erimit Actions |
||
Pharmacology: Pharmacokinetics:
Orally administered Erimit stearate is readily and reliably absorbed. Optimal serum levels of Erimit are reached when the drug is taken in the fasting state or immediately before meals.
Erimit diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the drug across the blood-brain barrier increases in meningitis. In the presence of normal hepatic function, Erimit is concentrated in the liver and excreted in the bile; the effect of hepatic dysfunction on excretion of Erimit by the liver into the bile is not known. Less than 5% of the orally administered dose of Erimit is excreted in active form in the urine.
Microbiology: Biochemical tests demonstrate Erimit inhibits protein synthesis of the pathogen without directly affecting nucleic acid synthesis. Antagonism has been demonstrated between clindamycin and Erimit.
Erimit binds to the 50S ribosomal subunits of susceptible bacteria and suppresses protein synthesis.
Erimit is usually active against most strains of the following organisms both in vitro and in clinical infections: Gram-Positive Organisms: Corynebacterium diphtheriae, Corynebacterium minutissimum, Listeria monocytogenes, Staphylococcus aureus (resistant organisms may emerge during treatment), Streptococcus pneumoniae, Streptococcus pyogenes.
Gram-Negative Organisms: Bordetella pertussis, Legionella pneumophilia, Neisseria gonorrhoeae.
Other Microorganisms: Chlamydia trachomatis, Entamoeba histolytica, Mycoplasma pneumoniae, Ureaplasma urealyticum.
Erimit has been shown to be active in vitro against most strains of the following organisms; however, the safety and efficacy of Erimit in treating infections due to these organisms have not been established in adequate and well-controlled trials: Gram-Positive Organisms: Alpha hemolytic streptococci (viridans group).
Gram-Negative Organisms: Moraxella (Branhamella) catarrhalis.
Other Microorganisms: Entamoeba histolytica, Treponema pallidum.
Disc Susceptibility Tests: Quantitative methods require measurement of zone diameters give the most precise estimates of antibiotic susceptibility. One recommended procedure uses Erimit class discs for testing susceptibility; interpretations correlate zone diameters of this disc test with MIC values for Erimit. With this procedure, a report from the laboratory of "susceptible" indicates the infecting organism is likely to respond to therapy. A report of "resistant" indicates the infective organism is not likely to respond to therapy. A report of "intermediate susceptibility" indicates the result be considered equivocal, and if, the pathogen is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category provides a buffer zone, which prevents small, uncontrolled technical factors from causing major discrepancies in interpretation.
Note: Many strains of Haemophilus influenzae are resistant to Erimit alone, but are susceptible to Erimit and sulfonamides together. Staphylococci resistant to Erimit may emerge during a course of Erimit therapy. Culture and susceptibility testing should be performed.
Take Erimit exactly as prescribed by your doctor. Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not take this medicine in larger or smaller amounts or for longer than recommended.
If a child is using this medicine, tell your doctor if the child has any changes in weight. Erimit doses are based on weight in children.
Do not crush, chew, or break a delayed-release Erimit. Swallow the tablet whole.
Use this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Erimit will not treat a viral infection such as the common cold or flu.
Erimit can cause unusual results with certain lab tests of the urine. Tell any doctor who treats you that you are using Erimit.
Store at room temperature away from moisture, heat, and light.
You may need to store liquid medicine in a refrigerator. Carefully follow the storage directions on your medicine label. Liquid medicine expires after a short period of time. Throw away any unused liquid as directed.
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
You may take Erimit with or without food.
Do not crush, chew, break, or open an Erimit tablet or capsule. Swallow it whole.
Shake the oral suspension (liquid) well just before you measure a dose. Measure the liquid with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.
This medication can cause unusual results with certain medical tests. Tell any doctor who treats you that you are using Erimit.
Take this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Erimit will not treat a viral infection such as the common cold or flu.
Store at room temperature away from moisture and heat, unless otherwise directed on the medicine label.
Orally administered Erimit ethylsuccinate suspensions and Filmtab tablets are readily and reliably absorbed. Comparable serum levels (Erimit ethylsuccinate) of Erimit are achieved in the fasting and nonfasting states.
Erimit diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the drug across the blood-brain barrier increases in meningitis. In the presence of normal hepatic function, Erimit is concentrated in the liver and excreted in the bile; the effect of hepatic dysfunction on excretion of Erimit by the liver into the bile is not known. Less than 5 percent of the orally administered dose of Erimit is excreted in active form in the urine.
Erimit crosses the placental barrier, but fetal plasma levels (Erimit ethylsuccinate) are low. The drug is excreted in human milk.
Erimit acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated in vitro between Erimit and clindamycin, lincomycin, and chloramphenicol.
Many strains of Haemophilus influenzae are resistant to Erimit alone but are susceptible to Erimit and sulfonamides used concomitantly.
Staphylocci resistant to Erimit may emerge during a course of therapy.
Erimit has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
Corynebacterium diphtheriae
Corynebacterium minutissimum
Listeria monocytogenes
Staphylococcus aureus(resistant organisms may emerge during treatment)
Streptococcus pneumoniae
Streptococcus pyogenes
Bordetella pertussis
Legionella pneumophila
Neisseria gonorrhoeae
Chlamydia trachomatis
Entamoeba histolytica
Mycoplasma pneumoniae
Treponema pallidum
Ureaplasma urealyticum
The following in vitro data are available, but their clinical significance is unknown.
Erimit exhibits in vitro minimal inhibitory concentrations (MIC's) of 0.5 μg/mL or less against most ( ≥ 90%) strains of the following microorganisms; however, the safety and effectiveness (Erimit ethylsuccinate) of Erimit in treating clinical infections due to these microorganisms have not been established in adequate and well controlled clinical trials.
Viridans group streptococci
Moraxella catarrhalis
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MIC's). These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC's should be determined using a standardized procedure. Standardized procedures are based on a dilution methodrequires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15-μg Erimit to test the susceptibility of microorganisms to Erimit.
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|